Oscar Health, Inc. (OSCR), the tech-driven health insurer leveraging AI for personalized plans and cost efficiencies, trades near $13 as of mid-February 2026—recovering from post-earnings volatility but undervalued amid sector headwinds. With record membership growth, improved margins, and bullish 2026 guidance signaling profitability, OSCR could rally toward $16–$17, delivering 25–30% upside as it scales in the $4 trillion U.S. healthcare market.
Core Platforms: Proven Reliability in the AI-Enabled Insurance Era
Oscar’s platform combines AI-driven risk adjustment, predictive analytics, and virtual care tools to deliver affordable, member-centric insurance. Key features include the +Oscar tech stack for seamless claims and lifestyle integrations (e.g., fitness rewards), achieving 91.1% MLR in 2025. Recent pilots with AI efficiencies reduced administrative costs by 160 basis points, while bronze/gold plan shifts boosted retention. Membership hit 3.4 million post-open enrollment (58% YoY growth), validating the model in competitive ACA markets.
Financial Deep Dive: Membership Boom and Margin Expansion
Oscar’s 2025 results impressed: full-year revenue $11.7 billion (28% YoY growth), beating estimates despite $396 million operating loss from risk accruals. Q4 MLR improved to 87.4%, with SG&A ratio at 17.5% (down 160 bps). Guidance for 2026 projects $18.7–$19 billion revenue (61% midpoint growth) and $250–$450 million operating earnings (near $750 million YoY improvement), implying 1.9% margins. Balance sheet includes strong liquidity (current ratio 4.2) and debt management, with EPS turning positive at $0.34 projected. Trailing 12-month revenue $12 billion, with free cash flow trends supporting the pivot.
Trading at ~15x forward EV/Revenue on 2026 midpoint, the multiple aligns with healthtech peers but undervalues the 43% revenue CAGR through 2027.
Analyst Bullishness: Consensus Targets Point to Substantial Re-Rating
Sentiment is mixed but improving: Hold consensus from 9–10 analysts (2 Buy, 5 Hold, 3 Sell), with average price target $15.40–$17 (up 15–25% from $13), ranging from $10 (low) to $23 (high). Recent upgrades include Raymond James to Outperform ($18) and UBS to Neutral ($17). Targets stable post-Q4, with 2026 EPS forecasts at $1.01 (up from -$0.03 prior).
Competitive Edge: Niche Leadership in Tech-Forward Health Insurance
Oscar differentiates with AI for morbidity management and member engagement, outperforming legacy insurers like UnitedHealth in cost control (MLR below consensus). Broker channel expansion and lifestyle innovations drive 28.5% PMPM growth projected for 2026. Versus peers like Clover Health, Oscar’s scale (3.4M members) and regulatory compliance provide moats in a consolidating $1 trillion individual market.
Risks and Long-Term Opportunity: Navigating Morbidity in Healthcare Shift
Headwinds include elevated risk adjustments (2025/2026 drag), macro enrollment volatility, and negative ROE (-44%). Beta ~1.8 amplifies swings, with shares down amid market morbidity. However, AI investments and membership ramps buffer; achieving 2026 profitability could catalyze re-rating in the $4 trillion sector’s digital transformation.
Oscar isn’t just insuring lives—it’s reimagining healthcare with AI precision. For value seekers in healthtech, this $13 dip offers a path to sustained gains.
Rating: Buy Grade: B+ Score: 89/100
FAQ
Q: What drove Oscar’s 61% 2026 revenue growth guidance? A: Record 3.4M membership (58% YoY) from open enrollment, plus AI efficiencies and plan mix shifts boosting PMPM by 28.5%.
Q: How is Oscar addressing 2025 losses? A: Through disciplined costs (SG&A down 160 bps), MLR improvements to 87.4%, and AI for risk management, targeting $250–$450M operating earnings in 2026.
Q: What’s the impact of Oscar’s +Oscar platform? A: It enables virtual care and predictive analytics, cutting admin expenses and enhancing retention in a competitive ACA landscape.